Truist Financial Sticks to Their Buy Rating for Catalyst Pharma (CPRX)
Truist Financial analyst Joon Lee reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report) today and set a price target of ...
Oppenheimer Keeps Their Buy Rating on Catalyst Pharma (CPRX)
Oppenheimer analyst Leland Gershell maintained a Buy rating on Catalyst Pharma (CPRX – Research Report) today and set a price target of ...
BioWorld18 天
MDA’s Kickstart program announces orphan drug designation for congenital myasthenic syndrome
The Muscular Dystrophy Association (MDA)’s Kickstart program has announced receipt of both U.S. orphan drug and rare pediatric disease designations in support of work for congenital myasthenic ...
WebMD18 天
Understanding Myasthenia Gravis: The Basics
When the muscles needed for breathing are affected, a patient is said to be in myasthenic crisis. This is a life-threatening situation. Though anyone can get myasthenia gravis, those most likely ...
BioSpace22 天
MDA Kickstart Program Receives FDA Rare Pediatric Disease Designation and Orphan Drug ...
The first project within the MDA Kickstart program is focused on congenital myasthenic syndrome due to mutations in the choline acetyltransferase gene (CHAT) and likely affects less than 250 people in ...